We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+49.66%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$813M
AUM Growth
+$268M
Cap. Flow
+$77.2M
Cap. Flow %
9.49%
Top 10 Hldgs %
63.05%
Holding
46
New
14
Increased
4
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
ALLK
Allakos
ALLK
+$24.9M
2
ASND icon
Ascendis Pharma A/S
ASND
+$23.7M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$19.7M
4
VRDN icon
Viridian Therapeutics
VRDN
+$18M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$18M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$29.2M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$27.9M
3
VTYX
Ventyx Biosciences
VTYX
+$20.3M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$14.9M
5
APLS
Apellis Pharmaceuticals
APLS
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$88.8M 10.92%
1,300,000
-200,000
-13% -$11.8M
CYTK icon
2
Cytokinetics
CYTK
$10.9B
$82.4M 10.13%
1,700,000
-50,000
-3% -$2.41M
IDYA icon
3
IDEAYA Biosciences
IDYA
$3.49B
$61.7M 7.58%
4,135,000
+385,000
+10% +$5M
VTYX
4
DELISTED
Ventyx Biosciences
VTYX
$48.8M 6%
1,397,680
-915,000
-40% -$20.3M
DSGN icon
5
Design Therapeutics
DSGN
$748M
$46.8M 5.75%
2,797,501
– –
BCYC
6
Bicycle Therapeutics
BCYC
$274M
$46.5M 5.72%
2,000,000
+300,000
+18% +$7.14M
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.7B
$38.7M 4.76%
350,000
-50,000
-13% -$5.04M
ALLK
8
DELISTED
Allakos
ALLK
$36.3M 4.47%
+5,936,666
New +$24.9M
KRTX
9
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$33.7M 4.15%
150,000
– –
ARQT icon
10
Arcutis Biotherapeutics
ARQT
$3.55B
$29.1M 3.58%
1,525,000
+525,000
+53% +$11.9M
DYN icon
11
Dyne Therapeutics
DYN
$4.19B
$29M 3.57%
2,287,321
-612,679
-21% -$7.02M
ALXO icon
12
ALX Oncology
ALXO
$279M
$28.4M 3.5%
2,971,352
-165,000
-5% -$1.92M
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$26.9M 3.31%
+1,500,000
New +$19.7M
ASND icon
14
Ascendis Pharma A/S
ASND
$16.8B
$25.8M 3.17%
+250,000
New +$23.7M
DICE
15
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$22M 2.71%
1,085,251
+100,000
+10% +$1.82M
VRDN icon
16
Viridian Therapeutics
VRDN
$2.18B
$20.5M 2.52%
+1,000,000
New +$18M
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.35B
$18.1M 2.22%
+500,000
New +$18M
IMCR icon
18
Immunocore
IMCR
$1.78B
$16.4M 2.02%
+350,000
New +$16.7M
FULC icon
19
Fulcrum Therapeutics
FULC
$251M
$15.8M 1.94%
1,950,000
– –
AKRO
20
DELISTED
Akero Therapeutics
AKRO
$13.6M 1.67%
+400,000
New +$6.12M
NGM
21
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$11.1M 1.37%
+850,000
New +$12.9M
OLMA icon
22
Olema Pharmaceuticals
OLMA
$1.07B
$10.3M 1.27%
3,743,875
– –
TCDA
23
DELISTED
Tricida, Inc. Common Stock
TCDA
$9.96M 1.22%
+950,000
New +$10.4M
ALT icon
24
Altimmune
ALT
$554M
$9.58M 1.18%
+750,000
New +$11.1M
BLU
25
DELISTED
BELLUS Health Inc.
BLU
$8.45M 1.04%
+800,000
New +$8.5M
1
2

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2022 Portfolio in Review

As of Q3 2022, Logos Global Management held 46 positions worth $813M, up 49% from $545M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Logos Global Management deployed $77.2M of net new capital in Q3 2022, opening 14 new positions and adding to 4 existing holdings. Its largest new stake was Allakos: 5,936,666 shares worth $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was Ventyx Biosciences, an estimated $20.3M trimmed.

  • Logos Global Management's largest Q3 2022 buy was Allakos: 5,936,666 shares worth $36.3M.
  • Logos Global Management added most to Arcutis Biotherapeutics in Q3 2022, an estimated $11.9M increase.
  • Logos Global Management's biggest Q3 2022 reduction was Ventyx Biosciences, cutting an estimated $20.3M.
  • Logos Global Management fully exited Neurocrine Biosciences in Q3 2022, selling an estimated $29.2M.
  • Logos Global Management's ten largest holdings make up 63% of its $813M portfolio in Q3 2022.
  • Logos Global Management opened 14 new positions and closed 7 in Q3 2022.
  • Logos Global Management's portfolio value rose 49% quarter-over-quarter to $813M.

Based on Logos Global Management's 13F filing for Q3 2022, filed 14 Nov 2022.